75835-35-7

Upstream product

• 123-91-1 1,4-dioxane 
• 1310-73-2 sodium hydroxide 
• 219764-59-7 benzyl 4-benzyloxy-2-chlorobenzoate 
• 56363-84-9 2-chloro-4-hydroxybenzoic acid 
• 2457-76-3 4-amino-2-chlorobenzoic acid 
• 100-44-7 benzyl chloride 

Downstream Products

• 75835-34-6 5-bezyloxyphenylglycine-2-carboxylic acid 
• 886447-20-7 4‐benzyloxy‐2‐chlorobenzoyl chloride 
• 439610-84-1 (S)-(+)-1-methylheptyl 4-benzyloxy-2-chlorobenzoate 
• 75835-38-0 N,O-diacetyl-6-benzyloxyindoxyl 
• 75835-36-8 anhydro-5-acetoxy-8-benzyloxy-2-hydroxyoxazolo<3,2-a>quinolinium hydroxide 
• 219573-63-4 2-chloro-4-benzyloxybenzyl chloride 
• 219764-63-3 3-(4-benzyloxy-2-chlorobenzyl)-2-methyl-3H-imidazo[4,5-b]pyridine-5-carboxylic acid 

Relevant academic research and scientific papers

Sulfonamide compounds and medicinal use thereof

A sulfonamide compound of the formula (I):R 1 --SO 2 NHCO--A--R 2 (I)wherein R 1 is alkyl, alkenyl, alkynyl and the like; A is an optionally substituted heteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R 2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.

IMIDAZOLE COMPOUNDS AND MEDICINAL USE THEREOF

Imidazole compounds represented by general formula (I): wherein each symbol is as defined in the specification, and salts thereof, and a pharmaceutical composition containing same are provided. These compounds are useful in treating the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy inhibitory action.

DOUBLE CYCLISATION OF PHENYLGLYCINE-o-CARBOXYLIC ACIDS - I NEW STABLE MESOIONIC OXAZOLONES

Remarkably stable mesoionic oxazolones possessing an oxazoloquinolinium structure (5a-b, 8, 16, 17) were obtained by the double cyclisation of phenylglycine-o-carboxylic acids (3a-c) in refluxing acetic anhydride or in benzoic anhydride at 140 deg.The O-Ac group was eliminated to give the corresponding lactones (6a-b) or replaced by O-Ts (7).IR stretching vibrations of the endo-carbonyl were in the range 1710-1768 cm-1, while ν1-CH exhibited unusually high values (3159-3194 cm-1). 1-Acyl derivatives could be obtained only with TFAA (23-24), although easydeuteration of the same position took place in the presence of traces of trifluoroacetic acid.Hydrolysis of 5b led to the α-quinolone-N-acetic acid 27a.In the case of 5a, hydrolysis was accompanied by self-acylation of the nucleophilic site at C-4 with formation of a dimeric acid 28a.The presence of an additional Me group in phenylalanine-o-carboxylic acid (36) activates the corresponding mesoionic oxazolone 37 so that 1-acylation becomes possible with formation of the fused oxazole 38 by the Dakin-West reaction.Temperature dependent magnetic non-equivalence of methylene protons has been observed in acids 3b-d and f and also in the 7-membered anhydride 48b.